Literature DB >> 25278312

Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.

S Valeri1, D Borzomati1, G Nappo2, G Perrone3, D Santini4, R Coppola1.   

Abstract

Neoadjuvant treatments (chemo or chemoradiation therapy) are used for patients with locally advanced Pancreatic Ductal Adeno-Carcinoma (PDAC). FOLFIRINOX is now considered an effective treatment modality for patients with metastatic pancreatic cancer and a promising option for patients with locally advanced PDAC. Complete pathologic response after neoadjuvant therapies is anecdotic and its prognostic impact is completely unclear. We report the case of a complete pathological response after treatment with FOLFIRINOX in a patient affected by a locally advanced PDAC with a review of the literature regarding the use of FOLFIRINOX for locally advanced PDAC.
Copyright © 2014 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complete pathological response; FOLFIRINOX; Locally advanced pancreatic cancer; Neoadjuvant chemotherapy; Neoadjuvant treatment; Pancreatic cancer

Mesh：

Substances：

Year:  2014        PMID： 25278312     DOI： 10.1016/j.pan.2014.07.002

Source DB:  PubMed          Journal:  Pancreatology        ISSN： 1424-3903            Impact factor:   3.996


  7 in total

1.  Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Authors:  Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

2.  Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI.

Authors:  Christos Nikolaou; Alexios Matikas; Maria Papavasilopoulou; Dimitris Mavroudis; Lampros Vamvakas
Journal:  Case Rep Oncol Med       Date:  2015-05-21

Review 3.  Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.

Authors:  Mišo Gostimir; Sean Bennett; Terence Moyana; Harman Sekhon; Guillaume Martel
Journal:  BMC Cancer       Date:  2016-10-10       Impact factor: 4.430

Review 4.  Neoadjuvant therapy for resectable pancreatic cancer.

Authors:  Sheikh Hasibur Rahman; Robin Urquhart; Michele Molinari
Journal:  World J Gastrointest Oncol       Date:  2017-12-15

5.  A nomogram prediction of overall survival based on lymph node ratio, AJCC 8th staging system, and other factors for primary pancreatic cancer.

Authors:  Rui Zhong; Xin Jiang; Yan Peng; Huan Xu; Yongfeng Yan; Li Liu; Xiaowei Tang
Journal:  PLoS One       Date:  2021-05-05       Impact factor: 3.240

6.  Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis.

Authors:  Rong Tang; Qingcai Meng; Wei Wang; Chen Liang; Jie Hua; Jin Xu; Xianjun Yu; Si Shi
Journal:  Gland Surg       Date:  2021-05

7.  Long-term Disease-free Survival Following Combination Multi-visceral and Metastatic Resection with Neoadjuvant FOLFIRINOX for Pancreatic Adenocarcinoma: A Case Report.

Authors:  Mikael Sodergren; Kirsty Brammer; David Cunningham; Satvinder Mudan
Journal:  Cureus       Date:  2015-12-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.